• Explore /
  • Poster
  • / EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).

EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).

Abstract Poster

Authors

Daniel Petrylak

Daniel Peter Petrylak

Yale University School of Medicine, New Haven, CT

Daniel Peter Petrylak , Jonathan E. Rosenberg , Ignacio Duran , Yohann Loriot , Guru Sonpavde , Chunzhang Wu , Elaina M Gartner , Amal Melhem-Bertrandt , Thomas Powles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT02091999

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr TPS497)

DOI

10.1200/JCO.2019.37.7_suppl.TPS497

Abstract #

TPS497

Poster Bd #

N7

Abstract Disclosures

Similar Posters

First Author: Christopher J. Hoimes

First Author: Jonathan E. Rosenberg

First Author: Ronac Mamtani

First Author: Peter H. O'Donnell